Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 28;8(12):e144.
doi: 10.1002/hem3.144. eCollection 2024 Dec.

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience

Idanna Innocenti  1 , Antonio Mosca  2 , Annamaria Tomasso  2 , Andrea Galitzia  3 , Lydia Scarfò  4   5 , Francesca Morelli  6 , Eugenio Galli  1   2 , Francesca Martini  4 , Eugenio Sangiorgi  7 , Roberta Laureana  8 , Giulia Benintende  9 , Veronica Mattiello  10 , Sabrina Chiriu  11 , Maria I Del Principe  8 , Giulia Zamprogna  12 , Massimo Gentile  13 , Enrica A Martino  13 , Emilia Cappello  14 , Maria C Montalbano  15 , Giuliana Farina  16 , Vanessa Innao  17 , Luca Stirparo  2 , Caterina Patti  18 , Paolo Sportoletti  19 , Alberto Fresa  1   2 , Gioacchino Catania  20 , Marta Coscia  15 , Silvia Bellesi  1 , Alessandra Tedeschi  21 , Alessandro Sanna  22 , Andrea Visentin  23 , Francesco Autore  1 , Raffaella Pasquale  24 , Livio Trentin  23 , Marzia Varettoni  25 , Paolo Ghia  4   5 , Roberta Murru  26 , Luca Laurenti  1   2
Affiliations

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience

Idanna Innocenti et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Paolo Ghia received honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Janssen, Lilly/LoxoOncology, MSD, and Roche, and research funding from AbbVie, AstraZeneca, BMS, and Janssen, and is an Editor of HemaSphere. Marzia Varettoni received honoraria from AbbVie, AstraZeneca, BeiGene, and Janssen. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Description of lymphocytosis in IGHV‐mutated and unmutated patients in the ibrutinib group (IBR) and acalabrutinib (ACALA) treatment arms. In both arms, the two curves followed a similar trend up to Month 6. However, the ACALA arm exhibited a sharper and deeper decline compared to IBR in the mutated group. This difference was observed solely in the median percentage of baseline, attributable to ACALA starting from higher baseline values.
See this image and copyright information in PMC

References

    1. Ahn IE, Brown JR. Targeting Bruton's Tyrosine Kinase in CLL. Front Immunol. 2021;12:12687458. - PMC - PubMed
    1. Hutchinson CV, Dyer MJS. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2014;166(1):12‐22. - PubMed
    1. Innocenti I, Fresa A, Tomasso A, et al. Treatment sequencing and outcome of chronic lymphocytic leukemia patients treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a thirty‐year single‐center experience. Cancers. 2023;15(23):5592. - PMC - PubMed
    1. Martino EA, Mauro FR, Reda G, et al. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: a retrospective real‐life multicenter Italian cohort. Hematol Oncol. 2024;42(1):e3249. - PubMed
    1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425‐2437. - PMC - PubMed

LinkOut - more resources